Oral presentation of a 48-week long Phase 3 clinical study on Generalized Myasthenia Gravis in China by Vor Bio scheduled at AANEM announced.
Vor Bio, a clinical-stage biotechnology company specialising in the treatment of autoimmune diseases, is making strides in the field with its novel dual-target fusion protein, telitacicept. This innovative drug is designed to treat autoimmune diseases by selectively inhibiting BLyS and APRIL, two cytokines essential to B cell and plasma cell survival.
Telitacicept has shown significant potential in a Phase 3 clinical trial for generalised myasthenia gravis (gMG), a rare, chronic autoimmune neuromuscular disorder that disrupts communication between nerves and muscles. Approximately 90,000 people in the United States, 140,000 in Europe, and 29,000 in Japan live with gMG, a disease that can impact mobility, vision, swallowing, and breathing.
The disease is mediated by autoantibodies, most commonly targeting the acetylcholine receptor (AChR) or muscle-specific kinase (MuSK). The dual-target mechanism of telitacicept reduces autoreactive B cells and autoantibody production, key drivers of autoimmune pathology.
In a Phase 3 clinical trial in China, telitacicept demonstrated a placebo-adjusted 4.83-point improvement in MG-ADL at 24 weeks, the primary endpoint of the trial. This promising result bodes well for its potential as a new therapy for gMG, which currently has a significant unmet need for treatments offering durable efficacy, a favourable safety profile, and convenient administration.
Vor Bio is conducting a global Phase 3 clinical trial for telitacicept in gMG to support its approval in the United States, Europe, and Japan. The trial is underway across the United States, Europe, South America, and Asia-Pacific.
The 48-week clinical data from this Phase 3 study will be presented as an oral presentation at the American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting in October 2025. The oral presentation will be titled 'Efficacy and Safety of Telitacicept in Patients with Generalised Myasthenia Gravis: Results from a Phase 3 Study'.
For more information about Vor Bio and its work, visit www.vorbio.com. For investor relations, contact Sarah Spencer at [email protected]. For media inquiries, contact Carl Mauch at [email protected]. The session for the oral presentation will take place on October 29, 2025, at 10:50am PT at the Hilton San Francisco Union Square in San Francisco, California.
Read also:
- Leading figures in the industry push for groundbreaking solutions to aid those affected by rare and neglected illnesses during the COVID-19 pandemic
- Ancient Fossilized Footprints Indicate Cohabitation of Two Hominin Species 1.5 Million Years Back
- "Unveiling the Inner Workings: An Exclusive Account of How the Manhattan Project Created the A-Bomb - Changing the Course of History"
- Healthcare Industry Suffers Cyber-Attacks by KillSec Ransomware on IT Infrastructures
